PSTV - PLUS THERAPEUTICS, INC.

0.828
0.039   4.698%

Share volume: 1,369,122
Last Updated: 04-07-2025
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: -0.01%

PREVIOUS CLOSE
CHG
CHG%
$0.79
0.04
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 43%
Dept financing 28%
Liquidity 18%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
6.85%
1 Month
-34.80%
3 Months
-31.00%
6 Months
-38.67%
1 Year
-56.19%
2 Year
-79.55%
Key data
Stock price
$0.83
P/E Ratio 
0.00
DAY RANGE
$0.69 - $0.88
EPS 
-$1.57
52 WEEK RANGE
$0.24 - $2.67
52 WEEK CHANGE
-$55.00
MARKET CAP 
8.609 M
YIELD 
N/A
SHARES OUTSTANDING 
5.896 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
1.31
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,997,624
AVERAGE 30 VOLUME 
$24,012,846
Company detail
CEO: Marc H. Hedrick
Region: US
Website: plustherapeutics.com
Employees: 20
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

Plus Therapeutics, Inc. focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma.

Recent news
loading